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Abstract
Objective: Serum prostate specific antigen (PSA) concentration has been 
widely applied as a biomarker to diagnose and monitor prostate cancer. 
Technetium-99m methylene diphosphate (Tc-99m MDP) whole body bone 
scintigraphy is currently a well-accepted diagnostic procedure for bone 
metastasis in malignancy. The aim of this study was to establish a useful 
serum PSA cut-off value to predict the presence of bone metastasis in men 
with prostate cancer.
Material and Methods: Consecutive male patients diagnosed with prostate 
cancer were retrospectively analyzed. All of the subjects had received 
both Tc-99m MDP whole body bone scintigraphy and had their serum PSA 
concentration measured within 1 month. The proper cut-off value was 
established based on statistical analysis in order to predict the possibility 
of bone metastasis among prostate cancer patients.
Results: In total, 101 consecutive male patients (age, 71.92 ± 0.76 years) 
with prostate cancer were enrolled, and 57 patients (56%) were confirmed 
by scintigraphic findings to have bone metastases. A serum PSA concentra-
tion of 13 ng/mL gave the best sensitivity (96.43%) and specificity (84.09%). 
The area under the receiver operating characteristics curve revealed excel-
lent discriminatory power (0.93 ± 0.02; p = 0.001). The positive predictive 
value, negative predictive value and likelihood ratios for positive and neg-
ative test were 88.52%, 94.87%, 6.06 and 0.04, respectively. The resulting 
diagnostic accuracy and odds ratio were 73.87% and 142.76.
Conclusion: A cut-off value of 13 ng/mL appears to be an appropriate 
benchmark for stratifying metastatic bone disease in prostate cancer 
patients such that if a patient with newly diagnosed prostate cancer and 
without any skeletal symptoms has a serum PSA concentration of less than 
13 ng/mL, we suggest that they would not need to undergo bone scintig-
raphy. [Tzu Chi Med J 2008;20(4):291–295]
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1. Introduction
Prostate cancer is one of the most commonly diag-
nosed malignancies in men. This leading cause of 
mortality has gradually increased throughout the world 
and results in more than 200,000 deaths annually 
[1]. In Taiwan, prostate cancer is the ninth leading 
cause of cancer-related death in male patients [2]. 
Although prostate cancer may be curable when it is 
identified at an early organ-confined stage, almost 
one fourth of patients present with advanced or met-
astatic disease at the time of diagnosis [3]. The most 
common site of metastatic spread in patients with 
prostate cancer is the skeleton, which accounts for up 
to 80% of all prostate cancer metastases [4]. Despite 
various therapeutic strategies, nearly half of patients 
with metastatic disease die within 30 months, and 
85–100% of those who die from prostate cancer have 
skeletal metastasis [5].
When bone metastasis develops, the influence is 
not only on the prognosis of the disease but also on 
the quality of life. The clinical characteristics of skel-
etal metastasis in prostate cancer include bone pain, 
impaired mobility, pathologic fracture, and spinal 
cord or nerve root compression. To select an appro-
priate treatment, detection of osseous metastasis is 
essential in patients with prostate cancer for both dis-
ease staging and the creation of a subsequent follow-
up plan. The current modality in clinical practice for 
assessing skeletal metastasis of prostate cancer is 
bone scintigraphy, which is a highly sensitive one-step 
procedure that uses whole body skeletal surveying. 
However, a serum tumor marker, prostate specific an-
tigen (PSA), is widely used as an initial biomarker to 
screen, monitor, and predict disease severity among 
prostate cancer patients. In addition, a rising PSA level 
may occur several months before changes in bone 
scintigraphy can be seen. Herein, the intention of our 
study was to determine the appropriate PSA cut-off 
value for predicting skeletal metastasis in patients 
with prostate cancer.
2. Materials and methods
2.1. Patients
From June 2001 to November 2005, 101 consecu-
tive patients with prostate cancer who underwent 
technetium-99m methylene diphosphate (Tc-99m 
MDP) whole body bone scintigraphy were retrospec-
tively analyzed. The information was collected from 
the scintigraphic database at a regional teaching 
hospital. Patients who did not have a serum PSA con-
centration available within 1 month before or after 
the time of performing the Tc-99m MDP whole body 
bone scintigraphy were excluded from this study. 
Since this was a retrospective study, the treatment 
status and clinical stage at enrolment were not scru-
tinized. In addition, all patients did not necessarily 
have a pathological report available. Bony metastases 
were determined from the bone scan studies and 
no further correlation with histopathology or other 
imaging modalities were performed. To preserve 
patient confidentiality, direct patient identifiers were 
not collected.
2.2. Bone scintigraphy
Tc-99m MDP is commercially available and was pro-
vided by Daiichi Radioisotope Labs, Ltd. (Tokyo, 
Japan). Following the Procedure Guideline for Bone 
Scintigraphy announced by the Society of Nuclear 
Medicine (version 3.0, approved June 20, 2003), a 
whole body bone scintigraphy scan (from the toes to 
top of the head) was performed using a whole-body 
moving camera technique (anterior and posterior) 
3–4 hours after intravenous injection of 20–25 mCi 
of Tc-99m MDP. All images were acquired using a two-
headed gamma camera scintillation system (DST-XL, 
General Electric Medical Systems, Buc, France) equip-
ped with large field-of-view, low-energy, high-resolution 
collimators. The energy peak and window level were 
set at 140 keV ± 20%. The matrix size was 512 ˜  2048 
pixels, and the scan speed was 16 cm/min. One in-
dependent nuclear medicine physician with more 
than 10 years of experience interpreted all scinti-
graphic images, the blind serum PSA levels and any 
available clinical findings. The final results were clar-
ified as negative (Fig. 1) or positive (Fig. 2) for skeletal 
metastasis, according to the bone absorption of the 
radiopharmaceutical.
2.3. PSA immunoradiometric assay
The serum PSA concentrations of all patients were 
measured by radioimmunometric assay (Immunotech-
PSA total IRMA kit; A Beckman Coulter Company, 
Fullerton, CA, USA). The principle of this assay is a 
“sandwich”-type assay. Serum or plasma samples are 
incubated in tubes coated with the first monoclonal 
antibody in the presence of the second monoclonal 
antibody, which is labeled with I-125. After incuba-
tion, the contents of the tubes are rinsed in order to 
remove unbound I-125 labeled antibody. The bound 
radioactivity was then measured in a gamma coun-
ter. The total PSA concentration in the sample is di-
rectly proportional to the radioactivity, and normal 
values were between 0 and 4 ng/mL. All examina-
tions, namely the scintigraphic imaging and the radio-
immunometric assays, were conducted in the same 
department.
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2.4. Statistical analysis
Statistical analyses were performed using MedCalc 
version 9.2 (MedCalc, Mariakerke, Belgium) for 
Windows, and expressed as mean ± standard error. 
In order to in spect the suitability of the various pos-
sible PSA cut-off points for predicting skeletal metas-
tasis in patients with prostate cancer, receiver 
operating characteristic (ROC) curve, sensitivity, spe-
cificity, diagnostic accuracy, positive predictive value 
(PPV), negative predictive value (NPV), likelihood 
ratio for a positive (LRP) test and likelihood ratio for 
a negative test (LRN) [6], Cohen’s kappa [7], and di-
agnostic odds ratio (DOR) [8] were used. The area 
under the ROC curve (AUC) with best sensitivity and 
specificity simultaneously were used as measurements 
to determine the diagnostic efficacy [9,10]. An AUC 
of 1.0 infers perfect discrimination, whereas an AUC 
between 1.0 and 0.8 is classified as “excellent” dis-
crimination, between 0.8 and 0.7 is “acceptable”, and 
≤ 0.5 is equivalent to a random model [11]. Cohen’s 
kappa was utilized to compare the proportion of cor-
rect test-based classifications with the proportion of 
correct classifications expected with a random as-
signation of diagnoses [12]. Cohen’s Kappa values 
indicate whether the agreement between measure-
ments was poor (< 0.20), fair (0.21–0.40), moderate 
(0.41–0.60), good (0.61–0.80), or very good (0.81–
1.00) [13]. The DOR of the cut-off point is calculated 
as the LRP/LRN ratio with higher values signifying 
better discriminatory power; specifically, this does 
not depend on the prevalence of the target disease 
[8]. The cut-off point of the serum PSA concentration 
for predicting skeletal metastasis in prostate cancer 
patients was judged to be optimal if it resulted in a 
high diagnostic accuracy, a high Cohen’s kappa and 
a high DOR.
3. Results
A total of 101 men with prostate cancer were enrolled 
in this study. Their mean age was 71.92 ± 0.76 years 
(range, 51–88 years), and mean serum PSA concentra-
tion was 124.94 ± 18.90 ng/mL (range, 0.10–838.00 ng/
mL). Of these, 57 patients (56.43%) were identified 
as having bone metastasis based on scintigraphic di-
agnosis. The statistical results for sensitivity, specifi-
city, PPV, NPV, diagnostic accuracy, LRP, LRN, Cohen’s 
kappa, and DOR of the various different PSA cut-off 
values are shown in Table 1. Serum PSA concentra-
tions between 15 ng/mL and 20 ng/mL gave the same 
statistical results as 15 ng/mL and so are not shown. 
The ROC analysis for predicting skeletal metastasis 
in prostate cancer resulted in an AUC of 0.93 ± 0.02, 
indicating that this gave good diagnostic efficiency and 
represented a statistically significant discriminatory 
power (p < 0.001), as shown in Fig. 3.
The PSA cut-off points of 13 ng/mL and 14 ng/mL 
gave good results and would be adequate for predicting 
Fig. 1 — A patient with “normal” bone scintigraphy. No 
definite bony destruction events are present in this Tc-99m 
MDP whole body bone scintigraphy scan of a patient with 
prostate cancer.
Fig. 2 — Multiple bony metastases are shown in this 
Tc-99m MDP whole body bone scintigraphy scan of a 
patient with prostate cancer.
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prostate cancer with an incremental screening value. 
However, a serum PSA cut-off point of 13 ng/mL re-
sulted in a higher DOR (142.76), sensitivity (96.43%), 
and NPR (94.87%). These were all higher than with a 
cut-off value of 14 ng/mL, but 13 ng/mL gave similar 
specificity (84.09%), PPR (88.52%), diagnostic accu-
racy (73.87%), LRP (6.06), LRN (0.04), and Cohen’s 
kappa (0.817) as 14 ng/mL.
4. Discussion
Prostate cancer has become one of the most com-
monly diagnosed cancers in men and is a leading 
cause of death among men throughout the world. An 
improvement in the clinical outcome of this disease 
would be accomplished if malignancy can be detected 
at an early organ-confined stage. Therefore, the estab-
lishment of a useful serum PSA level to predict the 
presence of bone metastasis in men with prostate 
cancer is a major concern.
Bone scintigraphy is a highly sensitive one-step 
procedure for whole body skeletal survey; it has been 
the gold standard for detecting skeletal metastasis of 
underlying malignancy in cancers such as prostate 
cancer. However, despite its high sensitivity, it is too 
expensive to be applied as a routine screening proce-
dure for bone metastasis. Measurement of serum 
tumor markers is another means of determining ma-
lignancy, and this approach is more cost-effective and 
more likely to achieve compliance in patients under-
going short- and/or long-term follow-up. It has become 
the most common test for detecting early prostate 
cancer and is widely used to monitor disease pro-
gression. An advancing clinical stage of prostate can-
cer, as well as the pathologic stage and tumor volume 
all result in a progressive increase in PSA level.
Rising PSA level will precede a patient’s worsening 
symptoms and can provide information several months 
before other diagnostic procedures in patients with 
prostate cancer metastasis. It is useful as evidence 
in developing countries where patients cannot afford 
bone scintigraphy. A diagnostic cut-off value has 
Table 1 — Sensitivity, specificity, positive predictive rate (PPR), negative predictive rate (NPR), diagnostic accuracy (DA), 
likelihood ratio positive (LRP) and negative (LRN), Cohen’s Kappa (K), and diagnostic odds ratio (DOR) for various 
cut-off values of serum prostate specific antigen concentration
Cut-off value 
Sensitivity (%)
 
Specificity (%) PPR (%) NPR (%) DA (%) LRP LRN K
 
DOR
(ng/mL)
 1.0 100.00 31.82 65.52 100.00 30.69 1.47 0.00 0.345 –
 2.0 98.24 38.64 67.47 94.44 35.14 1.60 0.05 0.395 35.15
 3.0 98.24 38.64 67.47 94.44 35.14 1.60 0.05 0.395 35.15
 4.0 98.24 43.18 69.14 95.00 38.74 1.73 0.04 0.442 42.42
 5.0 98.24 47.73 70.89 95.45 42.34 1.88 0.04 0.488 50.97
 6.0 98.24 47.73 70.89 95.45 42.34 1.88 0.04 0.488 50.97
 7.0 98.24 54.55 73.68 96.00 47.75 2.16 0.03 0.555 66.99
 8.0 98.24 54.55 73.68 96.00 47.75 2.16 0.03 0.555 66.99
 9.0 98.24 61.36 76.71 96.43 53.15 2.54 0.03 0.622 88.64
10.0 98.51 61.36 76.71 96.43 53.15 2.54 0.03 0.622 88.64
11.0 96.49 65.91 78.57 93.55 58.56 2.83 0.05 0.646 53.15
12.0 96.49 77.27 84.62 94.44 67.57 4.25 0.05 0.753 93.45
13.0* 96.43 84.09 88.52 94.87 73.87 6.06 0.04 0.817 142.76
14.0 94.74 86.36 90.00 92.68 76.58 6.95 0.06 0.817 114.04
15.0† 92.98 86.36 89.83 90.48 78.38 6.82 0.08 0.798 83.86
20.0† 92.98 86.36 89.83 90.48 78.37 6.89 0.08 0.798 83.86
*The best cut-off value for serum PSA concentration when predicting the presence of bone metastasis in prostate cancer patients; †the results of 
statistical analyses were the same for cut-off values of 15 ng/mL and 20 ng/mL.
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Fig. 3 — The receiver operating characteristic curve for 
predicting bone metastasis in prostate cancer patients.
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been established here based on several statistical 
analyses, and the best predictive value for prostate 
cancer patients with possible bone metastasis was 
found in this study to be 13 ng/mL. Our study result 
agrees quite well with that of Ishizuka et al [14], who 
suggested that bone scanning may not be necessary 
when the PSA level is less than 15 ng/mL. However, 
Chybowski et al [15] and Oesterling et al [16] both 
concluded that if a patient with newly diagnosed 
prostate cancer without skeletal symptoms has a 
serum PSA level of 10 ng/mL or less, then a staging 
bone scan is not necessary because such a PSA level 
is a strong negative predictor. Recently, some clini-
cians have discouraged the routine use of bone scan 
provided that the Gleason score is less than 7 (G1 or 
G2 tumors), except in patients with bone symptoms 
or a preoperative PSA level of 20 ng/mL or greater 
[15–17]. Due to the various different cut-off values that 
have been adopted, Rhoden et al [18] evaluated serum 
PSA cut-off values of 10 and 20 ng/mL for the predic-
tion of bone metastasis in prostate cancer patients. 
According to their results, a serum PSA concentra-
tion over 20 ng/mL is a more accurate threshold than 
10 ng/mL.
In our study, we did not only compare the cut-off 
points of 10 and 20 ng/mL, but also used a ROC curve 
and several indicators to establish an appropriate 
cut-off value for skeletal metastasis in patients with 
prostate cancer. However, there are some restrictions 
in this study. First, the number of enrolled patients 
was limited. More study patients should be enrolled 
in order to effectively lessen or avoid study bias. 
Second, bone scan images were interpreted by a sin-
gle well-trained nuclear medicine physician and the 
personal subjective point of view of this person in 
terms of image interpretation needs to be consid-
ered. Third, the serum PSA concentration and bone 
scintigraphy were not acquired on the same day, 
which is an imperfection that is inherent in a retro-
spective analysis of this type. Another limitation of 
our study is that patients were not assigned to spe-
cific groups, such as newly diagnosed, pathological 
histology status, Gleason score, digital rectal exami-
nation finding, etc. In a future prospective study, the 
blood specimen should be taken on the same day as 
the bone scan is performed. In addition, the study 
should be designed prospectively with a larger total 
sample of patients randomly selected from different 
hospitals to minimize inter-institutional variation, 
and finally, there should be full classification of the 
patients’ status.
In conclusion, our results showed that scintigraphic 
bone scanning is not essential in patients with newly 
diagnosed prostate cancer when their serum PSA 
level is less than 13 ng/mL, unless they have a history 
of bony involvement or the clinical examination is 
suggestive of such.
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